[
  {
    "ts": null,
    "headline": "Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)",
    "summary": "Gilead stock is downgraded to \"Buy\" as momentum cools despite strong Q3 beats, 2025 guidance, and upside valuation. Here's what you need to know.",
    "url": "https://finnhub.io/api/news?id=eb64ef0bba6fcf1cbf06d1a08858036aefb3daac0e9d530fda43f8847848602d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768570868,
      "headline": "Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)",
      "id": 138154610,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1208109286/image_1208109286.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead stock is downgraded to \"Buy\" as momentum cools despite strong Q3 beats, 2025 guidance, and upside valuation. Here's what you need to know.",
      "url": "https://finnhub.io/api/news?id=eb64ef0bba6fcf1cbf06d1a08858036aefb3daac0e9d530fda43f8847848602d"
    }
  },
  {
    "ts": null,
    "headline": "Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales",
    "summary": "Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted to faster development, manufacturing efficiency, and addressing prevalent diseases. Partnerships and innovation drive market growth.Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The \"Strategic Intelligence: Cell and Gene Therapy Investment Trends\" report has been added to ResearchAndMarkets.com's offerin",
    "url": "https://finnhub.io/api/news?id=889a66bfb7b7984695bd2bcc31b97b3e006e3c4a8c45162e9dd25e57304465b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768558980,
      "headline": "Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025-2031: Yescarta from Gilead Sciences and Zolgensma from Novartis Generated $1.5 Billion and $1.2 Billion in 2024 Sales",
      "id": 138150984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Cell and gene therapies present promising opportunities, especially in oncology, blood disorders, and neurology. Investors prioritize scalable platforms and clear regulatory paths. Focus has shifted to faster development, manufacturing efficiency, and addressing prevalent diseases. Partnerships and innovation drive market growth.Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The \"Strategic Intelligence: Cell and Gene Therapy Investment Trends\" report has been added to ResearchAndMarkets.com's offerin",
      "url": "https://finnhub.io/api/news?id=889a66bfb7b7984695bd2bcc31b97b3e006e3c4a8c45162e9dd25e57304465b9"
    }
  }
]